Orchestra BioMed Shares Trade Lower Ahead of Trial Milestone
Orchestra BioMed Holdings shares fell in Friday afternoon trade. Investors seemed to look ahead to upcoming milestones for its Medtronic-partnered hypertension therapy, while the news flow stayed quiet. The stock traded lower, falling 0.8% to $3.95 as roughly 116,000 shares changed hands. The move trailed the broader biotech sector, where the SPDR S&P Biotech ETF added 0.4%, but the iShares Nasdaq Biotechnology ETF slipped 0.2%.